Results 181 to 190 of about 910,008 (206)

NTRK fusions in thyroid cancer: Pathology and clinical aspects

Critical Reviews in Oncology/Hematology, 2023
Thyroid cancer is the most common endocrine cancer. Neurotrophic tyrosine receptor kinase (NTRK) fusions are oncogenic drivers in multiple solid tumors, including thyroid cancer. NTRK fusion thyroid cancer has unique pathological features such as mixed structure, multiple nodes, lymph node metastasis, and a background of chronic lymphocytic thyroiditis.
Yanhui Ma, Qi Zhang, Kexin Zhang, Yunzi liang, Fangbing Ren, Jingwen Zhang, Chengxia Kan, Fang Han, Xiaodong Sun   +8 more
openaire   +2 more sources

NTRK fusion‐positive colorectal cancer in Japanese population

Pathology International, 2021
ALK, ROS1 and NTRK fusions are involved in the tumorigenesis of various organs, including colorectal cancer. This study aims to clarify the prevalence of these fusions in colorectal cancer in the Japanese population. Immunohistochemical analysis of 1012 specimens of colorectal cancer revealed two NTRK‐positive cases (0.2%) whereas no ALK‐ or ROS1 ...
Junpei Yonemaru, Taiki Hashimoto, Daisuke Takayanagi, Tomoaki Naka, Yasushi Yatabe, Yukihide Kanemitsu, Kouya Shiraishi, Shigeki Sekine   +7 more
openaire   +2 more sources

China special issue on gastrointestinal tumors—NTRK fusion in a large real‐world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment

International Journal of Cancer, 2023
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers and targets of TRK inhibitors in solid tumors. Little is known about NTRK fusion in Chinese patients with pan‐cancer.
C. Qi, Ting Zhou, Yue-zong Bai, Hui Chen, Jiajia Yuan, Feilong Zhao, Chang Liu, Mingyang Ma, Ting Bei, Shiqing Chen, Xiaochen Zhao, Chun-Cheng R. Chen, L. Shen   +12 more
semanticscholar   +1 more source

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)

Journal of Clinical Oncology
PURPOSE The TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline ...
T. Laetsch, Stephan D. Voss, Kathleen Ludwig, David Hall, D. Barkauskas, Steven G Dubois, J. Ronan, E. Rudzinski, Amanda Memken, K. Robinson, J. Sorger, Joel M. Reid, T. Bhatla, B. Crompton, A. Church, E. Fox, Brenda J. Weigel   +16 more
semanticscholar   +1 more source

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer

2022
BackgroundFusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267), entrectinib (a TRK inhibitor with CNS activity) induced objective responses in 83.3% of patients (pts) with NTRK-fp ...
Lu, J., Blakely, C.M., Barve, M., Chung, C.H., Waqar, S.N., Hu, X., Delord, J-P., Krzakowski, M.J., Yonemori, K., Chen, D.T., Klingbiel, D., Heinzmann, S., Le Tourneau, C.   +12 more
openaire   +1 more source

ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors.

Journal of Clinical Oncology, 2023
3062 Background: The regulatory approval of TRK tyrosine kinase inhibitors (TKIs) represented a landmark in tissue-agnostic drug development. Adult and pediatric patients harboring NTRK fusions derive meaningful clinical benefits from the first ...
Karthigayini Sivaprakasam, G. Harada, N. Choudhury, Casey Savin, Ronak H. Shah, M. Berger, A. Drilon   +6 more
semanticscholar   +1 more source

Abstract 1075: Piloting NTRK fusion-specific oncogenicity guidelines - lessons learned

Cancer Research
Gene fusions involving neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, & NTRK3) are well-established oncogenic drivers and serve as critical diagnostic and therapeutic markers in cancer.
J. Saliba, Shivani Golem, Arpad M. Danos, Laura B. Corson, Elan Hahn, Morteza Seifi, Emma G. Sullivan, J. C. Santiago, Valentina Nardi, Ted Laetsch, Marilyn M. Li, O. Griffith, M. Griffith, G. Raca, Larissa V. Furtado, A. Church, Angshumoy Roy   +16 more
semanticscholar   +1 more source

Neurotrophic tropomyosin receptor kinase (NTRK) fusion positive tumors: a historical cohort analysis

Expert Review of Anticancer Therapy, 2023
Background NTRK gene fusions have been identified in various tumors; some requiring aggressive therapy and sometimes new TRK inhibitors (TRKi). We aimed to describe a national, unselected, retrospective, multicenter cohort.
L. Lemelle, D. Guillemot, A. Hermann, A. Gauthier, M. Carton, N. Corradini, A. Rome, P. Berlanga, Anne Jourdain, Aude Marie Cardine, S. Jannier, Hélène Boutroux, A. Defachelles, I. Aerts, B. Geoerger, M. Karanian, F. Doz, H. Brisse, G. Schleiermacher, O. Delattre, G. Pierron, D. Orbach   +21 more
semanticscholar   +1 more source

Identification of NTRK fusions in pediatric mesenchymal tumors

Pediatric Blood & Cancer, 2017
AbstractBackgroundNTRK fusions are known oncogenic drivers and have recently been effectively targeted by investigational agents in adults. We sought to assess the frequency of NTRK fusions in a large series of pediatric and adolescent patients with advanced cancers.ProcedureGenomic profiles from 2,031 advanced cancers from patients less than 21 years ...
Dean, Pavlick, Alexa B, Schrock, Denise, Malicki, Philip J, Stephens, Dennis J, Kuo, Hyunah, Ahn, Brian, Turpin, Justin M, Allen, Mark, Rosenzweig, Kamran, Badizadegan, Jeffrey S, Ross, Vincent A, Miller, Victor, Wong, Siraj M, Ali   +13 more
openaire   +2 more sources

NTRK fusions in colorectal cancer: clinical meaning and future perspective

Expert Opinion on Therapeutic Targets, 2021
Despite the efforts of the scientific community, the prognosis of metastatic colorectal cancer (mCRC) remains poor. Actionable gene fusions such as Neurotrophic Tropomyosin Receptor Kinases (NTRK) rearrangements are rare but might represent a new target to improve outcomes in this setting.
Margherita, Ratti, Giulia, Grizzi, Rodolfo, Passalacqua, Andrea, Lampis, Fabrizio, Cereatti, Roberto, Grassia, Jens Claus, Hahne   +6 more
openaire   +2 more sources